Pear Therapeutics (NASDAQ:PEAR – Get Rating) is one of 33 publicly-traded companies in the “Health services” industry, but how does it weigh in compared to its peers? We will compare Pear Therapeutics to related businesses based on the strength of its valuation, profitability, dividends, institutional ownership, analyst recommendations, risk and earnings.
This is a summary of current ratings and target prices for Pear Therapeutics and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Pear Therapeutics Competitors||7||130||274||0||2.65|
Pear Therapeutics currently has a consensus target price of $6.25, suggesting a potential upside of 215.66%. As a group, “Health services” companies have a potential upside of 117.59%. Given Pear Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Pear Therapeutics is more favorable than its peers.
Earnings & Valuation
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Pear Therapeutics||$4.21 million||-$65.14 million||-9.00|
|Pear Therapeutics Competitors||$1.36 billion||-$98.47 million||29.16|
Pear Therapeutics’ peers have higher revenue, but lower earnings than Pear Therapeutics. Pear Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
55.4% of Pear Therapeutics shares are owned by institutional investors. Comparatively, 48.6% of shares of all “Health services” companies are owned by institutional investors. 30.7% of Pear Therapeutics shares are owned by company insiders. Comparatively, 21.6% of shares of all “Health services” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Pear Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Pear Therapeutics Competitors||-325.87%||-481.74%||-38.64%|
Volatility and Risk
Pear Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Pear Therapeutics’ peers have a beta of 1.48, meaning that their average stock price is 48% more volatile than the S&P 500.
Pear Therapeutics beats its peers on 8 of the 12 factors compared.
About Pear Therapeutics
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.
Receive News & Ratings for Pear Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pear Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.